Title |
Intravesical gemcitabine for non‐muscle invasive bladder cancer
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2012
|
DOI | 10.1002/14651858.cd009294.pub2 |
Pubmed ID | |
Authors |
Gabriel Jones, Anne Cleves, Timothy J Wilt, Malcolm Mason, Howard G Kynaston, Mike Shelley |
Abstract |
Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer is a well established treatment for preventing or delaying tumour recurrence following tumour resection. However, up to 70% of patients may fail and new intravesical agents with improved effectiveness are needed. Gemcitabine is a relatively new anticancer drug that has shown activity against bladder cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | <1% |
Unknown | 107 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 20 | 19% |
Student > Postgraduate | 14 | 13% |
Student > Bachelor | 10 | 9% |
Researcher | 9 | 8% |
Other | 8 | 7% |
Other | 16 | 15% |
Unknown | 31 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 44 | 41% |
Nursing and Health Professions | 8 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Social Sciences | 3 | 3% |
Psychology | 3 | 3% |
Other | 10 | 9% |
Unknown | 36 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2018.
All research outputs
#3,289,155
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#5,914
of 11,499 outputs
Outputs of similar age
#25,222
of 251,894 outputs
Outputs of similar age from Cochrane database of systematic reviews
#84
of 227 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,894 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 227 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.